---
title: "editorial doxycycline sti postexposure prophylaxis"
year: 2024
month: 10
journal: "American Family Physician"
volume: "109-110"
issue: "10"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2024-10-editorial-doxycycline-sti-postexposure-prophylaxis.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# editorial doxycycline sti postexposure prophylaxis

Editorials


Practice Alert:​CDC Guidelines on Doxycycline
for STI Postexposure Prophylaxis
Doug Campos-Outcalt, MD, MPA




T      he Centers for Disease Control and Prevention (CDC)
       recently released guidelines on the use of doxycycline for
postexposure prophylaxis of gonorrhea, chlamydia, and syph-
                                                                         has been shown to prevent gonorrhea, chlamydia, and syph-
                                                                         ilis. However, studies included predominantly HIV-positive
                                                                         MSM and transgender women.4-6 Although the magnitude
ilis.1 This is an important document given the decades-long              of the protection differed by study, in one study, the number
trend of increasing incidence of these three sexually transmitted        needed to treat to prevent one STI per 3 months was 4.7.5 In
infections (STIs) and the current lack of a vaccine. The CDC             another study, a mean of 43 doses of postexposure prophylaxis
recommends that clinicians discuss prescribing doxycycline               prevented 1.3 infections in 1 year.6
postexposure prophylaxis to prevent bacterial STIs with men                 Because of the lack of evidence in other populations and a
who have sex with men (MSM), and transgender women, who                  concern about possible antibiotic resistance with long-term,
have had a bacterial STI in the past year.                               widespread use, the CDC recommends doxycycline postex-
   The epidemiology of gonorrhea, chlamydia, and syphilis                posure prophylaxis only for MSM, and transgender women,
differ, reflecting different sexual networks. The most recent            who have received a bacterial STI diagnosis in the previous
complete data are from 2022.2 In that year, the incidence rate           year. Eligible patients should be counseled about the possible
of chlamydia was 495.0 per 100,000 people (363.7 per 100,000             benefits of doxycycline postexposure prophylaxis and provided
men, 621.2 per 100,000 women). The highest incidence was                 with a prescription for self-administration that lasts until the
in those 15 to 24 years of age. The incidence rate for gonor-            next planned visit. Practical tips for maximizing benefit and
rhea was 194.4 per 100,000 people (236.3 per 100,000 men,                minimizing harm from doxycycline include:​
152.1 per 100,000 women). The age group with the highest                    • No more than 200 mg should be taken in 24 hours.
incidence of gonorrhea was slightly older than for chlamydia                • Doxycycline should be taken on a full stomach with a full
at 20 to 29 years. Syphilis had an incidence rate of 62.2 per            glass of liquid, and the patient should avoid lying down for
100,000 people. Primary and secondary syphilis, which indi-              1 hour.
cate recent infection, had rates of 26.8 per 100,000 men and                • Doxycycline should not be taken within 2 hours of con-
8.7 per 100,000 women, with the highest rates occurring in               suming dairy products, antacids, or other products containing
those 25 to 34 years of age. Infections in MSM are the largest           calcium.
contributors to syphilis trends and important contributors to               • Check for potential interactions with other medications the
gonorrhea trends.                                                        patient is currently taking.
   Changes in social networking due to the COVID-19 pan-                    In addition to counseling about and prescribing doxycycline
demic altered the trajectory of these infections. Between 2021           for these high-risk populations, family physicians should offer
and 2022, the rate of chlamydia increased slightly by 0.3%,              screening for STIs, including HIV;​screening for hepatitis B
gonorrhea declined by 8.7%, and syphilis increased by 17%.               and C;​and counseling about other preventive measures, such as
Of particular concern, the rate of congenital syphilis increased         condom use and HIV preexposure prophylaxis. Family physi-
by 30.6%, with 3,755 cases reported in 2022.2 Congenital                 cians should also provide all indicated vaccines, including those
syphilis is a preventable condition with early and appropriate           to prevent hepatitis A and B, human papillomavirus, mpox
prenatal care.3                                                          (monkeypox), and meningococcal meningitis.
   Doxycycline, 200 mg, administered within 24 hours and no                 Although doxycycline postexposure prophylaxis recommen-
later than 72 hours after condomless oral, vaginal, or anal sex          dations target a limited, defined population, the CDC also
                                                                         states that physicians should use their clinical judgment and
                                                                         shared clinical decision-making to decide on doxycycline use
   DOUG CAMPOS-OUTCALT, MD, MPA, University of
                                                                         with other patients at high risk of STIs.
   Arizona, Phoenix.

   Author disclosure:​No relevant financial relationships.               REFERENCES
                                                                          1. Bachman LH, Barbee LA, Chan P, et al. CDC clinical guidelines on the
   Address correspondence to Doug Campos-Outcalt, MD,
                                                                             use of doxycycline postexposure prophylaxis for bacterial sexually
   MPA, at dougco@​arizona.edu.                                              transmitted infection prevention, United States, 2024. MMWR
                                                                             Recomm Rep. 2024;​73(2):​1-8.


              Downloaded from the American Family Physician website at www.aafp.org/afp. Copyright © 2024 American Acad-
338 American Family Physician	                                                                            Volume 110, Number 4 • October 2024
               emy of Family Physicians. For the private, noncommercial use of one individual user of the website. All other rights
                           reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                                                                                                                                        EDITORIALS

 2. Center for Disease Control and Prevention. National Center for                                randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis.
    HIV, Viral Hepatitis, STD and TB Prevention. Sexually transmitted                             2018;​18(3):​308-317.
    infections. Surveillance 2022. Accessed August 25, 2024. https://​                         5. Luetkemeyer AF, Donnell D, Dombrowski JC, et al.;​DoxyPEP Study
    www.cdc.gov/std/statistics/2022/slides/2022-STI-Surveillance-All-                             Team. Postexposure doxycycline to prevent bacterial sexually
    Slides.pptx                                                                                   transmitted infections. N Engl J Med. 2023;​388(14):​1296-1306.
 3. Lin KW. Closing primary and prenatal care gaps to prevent congenital                       6. Molina JM, Bercot B, Assoumou L, et al. Conference on Retroviruses
    syphilis [published correction appears in Am Fam Physician. 2021;​                            and Opportunistic Infections. ANRS 174 DOXYVAC:​an open-label
    103(1):​8]. Am Fam Physician. 2020;​102(2):​78-79.                                            randomized 253 trial to prevent STIs in MSM on PrEP. Abstract
 4. Molina JM, Charreau I, Chidiac C, et al.;​ANRS IPERGAY Study Group.                           119. Accessed August 25, 2024. https://​w ww.croiconference.org/
    Post-exposure prophylaxis with doxycycline to prevent sexually                                abstract/anrs-174-doxyvac-an-open-label-randomized-trial-to-
    transmitted infections in men who have sex with men:​an open-label                            prevent-stis-in-msm-on-prep/ ■




                                                                                              It is the policy of the AAFP that all individuals in a position to control CME content
AFP Directory                                                                                 disclose any relationships that they or their spouse/partner have with commercial entities.
                                                                                              Further, should any such relationship be determined to be in possible conflict of interest
• Article proposals—Sumi M. Sexton, MD, editor-in-chief; afpjournal@aafp.org.
                                                                                              as it relates to the individual’s proposed role in the CME activity, the conflicts of interest
• Reader feedback—afpedit@aafp.org.
                                                                                              must be resolved before confirmation of the individual’s participation. We inform read-
• Letters to the Editor—See instructions at https://www.aafp.org/afp/authors.
                                                                                              ers of any pertinent relationships disclosed. A disclosure statement is published at the
• Display advertising—Darren Sextro, Vice President of Journal Media; dsextro@
                                                                                              beginning of relevant articles. The medical and professional editors of AFP in a position
   aafp.org
                                                                                              to control content for this activity, AFP, have indicated they have no relevant financial
• Classified advertising—Community Brands, aafp@community​brands.com;
                                                                                              relationships to disclose.
   727-497-6568
• Other AAFP information—800-274-2237                                                        Editorial Mission
                                                                                              To empower family physicians to improve the health of patients and communities as the
Subscriptions, delivery problems, address changes
                                                                                              leading source of medical information while advancing science and health equity.
AAFP Member Resource Center: 800-274-2237; aafp@aafp.org. To subscribe, visit
https://www.aafp.org/afp/subscribe. One-year print and digital subscription (12 issues):      CME Objectives
AAFP student members, $45; AAFP international members, $120; physicians and other             1.	Apply learned concepts to the diagnosis, screening, and treatment of clinical condi-
individuals, $300 (U.S.).; institutions, $775 (U.S.). Nonmember medical students,                 tions managed by family physicians.
residents, allied health care professionals, and medical office management staff, $190        2.	Identify the strengths and weaknesses of diagnostic and treatment strategies.
(U.S.). Payment must be accompanied by identification of profession. For complete             3.	Determine the most effective treatment strategy based on best available evidence in the
rates outside the U.S, plus digital-only rates, go to https://www.aafp.org/afp/subscribe.         literature.
Remit in U.S. dollars, drawn on a U.S. bank. All subscriptions include web access and         4.	Differentiate and implement practice recommendations from evidence-based guide-
the mobile app edition. Print copies of back issues are $40 per issue (plus shipping for          lines and consensus guidelines rather than personal opinion.
addresses outside the U.S.), volume discounts available. Online access to restricted issues
is $59.95 per issue.
                                                                                              About Advertising and Funded Activities
                                                                                              The AAFP accepts paid advertising and externally funded education in certain of its
Permission to reuse material from AFP                                                         publications including American Family Physician (AFP) print and digital channels.
• Academic, noncommercial use—Go online to https://www.copyright.com and enter               The revenue associated with these commercial investments helps to support numerous
   ISSN 0002-838X in the search box or contact the Copyright Clearance Center (info@          activities of the AAFP, including the publishing expenses of professional journals like
   copy​right.com; 978-750-8400; fax: 978-646-8700).                                          AFP. Funding, including for advertising, is accepted only if judged to be consistent with
• Bulk reprints, e-prints—John Wiley & Sons, Inc; 781-325-3749; commercial​                  the interests of family physicians, and funding standards are both formalized and ever
   reprints@​wiley.com.                                                                       evolving. The AAFP and its publishing management reserve the right to disallow any
• Other requests—copyrights@aafp.org.                                                        advertising or funded activities at their discretion. The acceptance of funded activities
                                                                                              never indicates or implies AAFP or AFP endorsement of a company or product or service,
Editorial Policies                                                                            nor is funding ever allowed to influence the independence of editorial content at any stage
The information and opinions presented in AFP reflect the views of the authors, not           of its development in any channel. Funded content, including advertising, that adopts an
those of the journal or the AAFP, unless so stated. AFP publishes drug trade names for        “editorial-like” format, through either design or written approach, is appropriately labeled
the readers’ convenience only; names are based on what is currently available. This does      to alleviate any potential confusion. The journal editors have no part in the development
not imply endorsement of any product by AFP or the AAFP.                                      of such funded content, including advertising.


October 2024 • Volume 110, Number 4                                                                                                             American Family Physician 339
